Home
ARVN
ARVN News

Latest Arvinas Inc. (ARVN) News on April 23, 2025

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

GlobeNewswire

2 days ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

Insider Monkey

14 days ago

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)

Zacks

14 days ago

After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)

MT Newswires

14 days ago

Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Benzinga

19 days ago

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

Clinical Trials Arena

19 days ago

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

MT Newswires

19 days ago

Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

GlobeNewswire

19 days ago

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Simply Wall St.

20 days ago

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

GlobeNewswire

a month ago

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Zacks

a month ago

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

Insider Monkey

a month ago

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

Zacks

a month ago

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Zacks

a month ago

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Biotech Alert: Searches spiking for these stocks today

TipRanks

a month ago

Biotech Alert: Searches spiking for these stocks today

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Zacks

a month ago

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Zacks

a month ago

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

Zacks

a month ago

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

MT Newswires

a month ago

Goldman Sachs Downgrades Arvinas to Neutral From Buy, Cuts Price Target to $15 From $70

MT Newswires

a month ago

Arvinas' Vepdegestrant Likely to Have 'Restricted Label' in Breast Cancer, Wedbush Says

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study

Zacks

a month ago

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study

MT Newswires

a month ago

Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

Investor's Business Daily

a month ago

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

MT Newswires

a month ago

Citigroup Cuts Arvinas' Price Target to $10 From $19, Maintains Neutral Rating

MT Newswires

a month ago

Top Midday Decliners

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients

Clinical Trials Arena

a month ago

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients

MT Newswires

a month ago

Oppenheimer Downgrades Arvinas to Perform From Outperform

MT Newswires

a month ago

Sector Update: Health Care

MT Newswires

a month ago

Arvinas, Pfizer Say Vepdegestrant Trial Meets Primary Endpoint in Breast Cancer With ESR1 Mutations

MT Newswires

a month ago

Top Premarket Decliners

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

GlobeNewswire

a month ago

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

2 months ago

Arvinas to Participate in Upcoming Investor Conferences

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

Zacks

2 months ago

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

MT Newswires

2 months ago

Arvinas Insider Sold Shares Worth $523,881, According to a Recent SEC Filing

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago

Simply Wall St.

2 months ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

Zacks

2 months ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

Zacks

2 months ago

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Arvinas Inc Earnings Call

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...

GuruFocus.com

2 months ago

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Zacks

2 months ago

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

MT Newswires

2 months ago

Arvinas' Q4 Loss Narrows, Revenue Misses Analysts' Expectations

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire

2 months ago

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings

GuruFocus.com

2 months ago

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

GlobeNewswire

3 months ago

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Motley Fool

3 months ago

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

MT Newswires

3 months ago

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

GlobeNewswire

3 months ago

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Clinical Trials Arena

4 months ago

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

Benzinga

4 months ago

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

MT Newswires

4 months ago

Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

4 months ago

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Insider Monkey

5 months ago

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

5 months ago

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire

5 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Insider Monkey

5 months ago

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Arvinas Third Quarter 2024 Earnings: Beats Expectations

MT Newswires

6 months ago

UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

GuruFocus.com

6 months ago

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

MT Newswires

6 months ago

Arvinas' Q3 Net Loss Narrows, Revenue Rises

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Zacks

6 months ago

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

6 months ago

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

6 months ago

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Simply Wall St.

6 months ago

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Insider Monkey

6 months ago

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

GlobeNewswire

6 months ago

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

GlobeNewswire

6 months ago

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago

Simply Wall St.

7 months ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares

GuruFocus.com

7 months ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Insider Monkey

8 months ago

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

8 months ago

Arvinas to Participate in Upcoming Investor Conferences

Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts

Simply Wall St.

9 months ago

Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Simply Wall St.

9 months ago

Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

MT Newswires

9 months ago

Oppenheimer Adjusts Arvinas Price Target to $50 From $70, Maintains Outperform Rating

MT Newswires

9 months ago

Arvinas' Q2 Net Loss Narrows as Revenue Rises; Names Andrew Saik CFO

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Zacks

9 months ago

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

GlobeNewswire

9 months ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

Biotech Arvinas Stock Earns 82 RS Rating

Investor's Business Daily

9 months ago

Biotech Arvinas Stock Earns 82 RS Rating

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

Zacks

9 months ago

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

Milestone Pharmaceuticals Refreshes Board of Directors

GlobeNewswire

9 months ago

Milestone Pharmaceuticals Refreshes Board of Directors

Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?

Insider Monkey

10 months ago

Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?

MT Newswires

10 months ago

Arvinas Names Andrew Saik as Chief Financial Officer; Shares Rise After Hours

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

GlobeNewswire

10 months ago

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

Zacks

10 months ago

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

GlobeNewswire

10 months ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

GlobeNewswire

10 months ago

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

CNW Group

10 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

CNW Group

10 months ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

PR Newswire

10 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

Business Wire

10 months ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts

AFP

10 months ago

New Zealand scraps plan to tax livestock burps, farts

Business Wire

10 months ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

The Wall Street Journal

10 months ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool

Bloomberg

10 months ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Arvinas to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

GlobeNewswire

a year ago

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope

Simply Wall St.

a year ago

It Looks Like Arvinas, Inc.'s (NASDAQ:ARVN) CEO May Expect Their Salary To Be Put Under The Microscope

MT Newswires

a year ago

Sector Update: Health Care Stocks Steady Premarket Thursday

Share on Social Networks: